How drugmakers became masters at producing authorized generics
When PDL BioPharma ’s $40 million blood-pressure medicine faced the threat of a generic rival this year, the company pulled out a little-known strategy that critics say helps keep drugs expensive and competition weak. It launched its own generic version of Tekturna, a pill taken daily by thousands. PDL’s “author ized” copycat hit the market in March, […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - August 14, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/jay-hancock-and-sydney-lupkin" rel="tag" > Jay Hancock and Sydney Lupkin < /a > < /span > Tags: Meds Medications Source Type: blogs
ATMOSPHERE: Heart Failure Trial Poisoned By Controversy
–Aliskiren raised regulatory pandemonium as it crashed in trials When it comes to interrupting the renin-angiotensin system, the third time was definitely not the charm. Following the enormous success of the ACE inhibitors and angiotensin-receptor blockers, there were early high expectations for a third class of drugs, the direct renin inhibitors. Those hopes were dashed...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - April 4, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics aliskiren Novartis renin inhibitor Renin-angiotensin system Tekturna Source Type: blogs
DM / DNB Cardiology Entrance Mock Test 7
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.
If loading fails, click here to try again
Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. There is no time limit for this mock test.
Start
Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 7.
You scored %%SCORE%% out of %%TOTAL%%.
Your performan...
Source: Cardiophile MD - January 23, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
Cardiology MCQ: Add on therapy in heart failure
Preferred add on therapy in heart failure,
to ACE inhibitors and beta blockers:
a) Angiotensin receptor blocker
b) Mineralocorticoid antagonist
c) Renin antagonist
d) None of the above
Correct answer: b) Mineralocorticoid antagonist
Mineralocorticoid antagonist like spironolactone or eplerenone is the add on therapy in heart failure to angiotensin converting enzyme inhibitors (ACEI) and beta blockers in the management of heart failure. Spironolactone has been shown to reduce myocardial fibrosis and corrected QT interval (QTc) [Wong KY et al. Myocardial fibrosis and QTc are reduced following treatment with spironolactone or...
Source: Cardiophile MD - November 29, 2014 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Cardiology MCQ 324: Add on therapy in heart failure
Preferred add on therapy to ACE inhibitors and beta blockers in heart failure:
a) Angiotensin receptor blocker
b) Mineralocorticoid antagonist
c) Renin antagonist
d) None of the above
["Click here for the answer with explanation", "Correct Answer:"]
b) Mineralocorticoid antagonist
Mineralocorticoid antagonist like spironolactone or eplerenone is the preferred add on therapy to angiotensin converting enzyme inhibitors (ACEI) and beta blockers in the management of heart failure. Angiotensin receptor blockers (ARB) and renin antagonist (e.g. aliskiren) are not preferred. ARBs with proven benefit in heart failure like ...
Source: Cardiophile MD - September 28, 2014 Category: Cardiology Authors: Prof. Dr. Johnson Francis MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Novartis Recalls Millions Of Samples Due To Packaging Glitch
Here is a headache no drugmaker wants to endure. Last July, Novartis began recalling a few million bottles of samples of different medicines that were distributed to physicians, because routine testing determined that a chemical used in shrink wrap packaging was found to leech into some tablets. The incident appears to be an unusual instance in which samples given to doctors have been yanked.
The voluntary recall amounted to 127 lots of samples for three blood pressure treatments - Exforge, Tekturna and Diovan – as well as the Lescol cholesterol pill and the Stalevo Parkinson’s drug, although a Novartis spokeswoman was...
Source: Pharmalot - December 20, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Summary of Recent Settlements Novartis, Amgen and Boehringer Ingelheim
Discussion
In light of these cases, and in particular, the Novartis kickback case, Jose Sierra, a white collar lawyer who writes for the blog pharmarisc, proposed several factors for companies to consider.
Companies must ensure close monitoring of speaker programs to ensure compliance with internal policies and CIA requirements
For "front-end" controls, he recommends that companies should adopt a system in which no speaker program is scheduled without 6-10 "RSVPs" from invited doctors. "You need this many RSVPs because half the doctors never show up and 3-5 attendees are needed to pass the laugh test....
Source: Policy and Medicine - July 19, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
Risk of angioedema in ACEIs versus ARBs versus aliskiren
(Source: Notes from Dr. RW)
Source: Notes from Dr. RW - May 31, 2013 Category: Internists and Doctors of Medicine Tags: pharmacology cardiovascular Source Type: blogs
Pharmalot… Pharmalittle… The Weekend Nears
Ready, get set, start daydreaming about the weekend. Another working week is about to draw to a close and already we are making our list of things to enjoy. These include spending time with the short people, catching up on some reading and taking a trip down the proverbial memory lane. But what about you? There are myriad ways to keep warm during this cold snap, such as gathering ’round the fireplace, taking in a movie at a theater that actually turns up the thermostat or downing a shot of scotch. The rest we will leave to your imagination. Whatever you do, have a grand time, but be safe. See you soon…
Novarti...
Source: Pharmalot - January 25, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Actavis New England Compounding Center Novartis Roche Tekturna Vaccines Watson Pharmaceuticals Source Type: blogs
